APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Receptor Superfamily Member 9

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Growth and Trends Forecast to 2032

Report ID 174043760119 December 202587 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Receptor Superfamily Member 9 Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

According to APO Research, the global Tumor Necrosis Factor Receptor Superfamily Member 9 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Tumor Necrosis Factor Receptor Superfamily Member 9 market include Eli Lilly and Co, Pfizer Inc, Pieris Pharmaceuticals Inc, MacroGenics Inc, Juno Therapeutics Inc, BioInvent International AB, Apogenix GmbH, Alligator Bioscience AB and Agenus Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Tumor Necrosis Factor Receptor Superfamily Member 9 market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Tumor Necrosis Factor Receptor Superfamily Member 9 market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Tumor Necrosis Factor Receptor Superfamily Member 9.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Tumor Necrosis Factor Receptor Superfamily Member 9 market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Company

Eli Lilly and Co

Pfizer Inc

Pieris Pharmaceuticals Inc

MacroGenics Inc

Juno Therapeutics Inc

BioInvent International AB

Apogenix GmbH

Alligator Bioscience AB

Agenus Inc

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Type

Ultra-41BBL

PRS-342

ISAS-01

EU-101

Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Application

Gastric Cancer

Lymphoma

Cervical Cancer

Bladder Cancer

Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily Member 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily Member 9.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 9 companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2021-2026) Table 4. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2027-2032) Table 6. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Type (2021-2026) Table 9. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share Forecasted by Type (2027-2032) Table 11. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2021-2026) Table 24. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share Forecasted by Application (2027-2032) Table 26. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends Table 37. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Drivers Table 38. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Opportunities and Challenges Table 39. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Restraints Table 40. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Company (2021-2026) Table 42. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Key Company Headquarters & Area Served Table 44. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company, Product Type & Application Table 45. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Tumor Necrosis Factor Receptor Superfamily Member 9 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Eli Lilly and Co Company Information Table 49. Eli Lilly and Co Business Overview Table 50. Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 52. Eli Lilly and Co Recent Development Table 53. Pfizer Inc Company Information Table 54. Pfizer Inc Business Overview Table 55. Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 57. Pfizer Inc Recent Development Table 58. Pieris Pharmaceuticals Inc Company Information Table 59. Pieris Pharmaceuticals Inc Business Overview Table 60. Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 62. Pieris Pharmaceuticals Inc Recent Development Table 63. MacroGenics Inc Company Information Table 64. MacroGenics Inc Business Overview Table 65. MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 67. MacroGenics Inc Recent Development Table 68. Juno Therapeutics Inc Company Information Table 69. Juno Therapeutics Inc Business Overview Table 70. Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 72. Juno Therapeutics Inc Recent Development Table 73. BioInvent International AB Company Information Table 74. BioInvent International AB Business Overview Table 75. BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 77. BioInvent International AB Recent Development Table 78. Apogenix GmbH Company Information Table 79. Apogenix GmbH Business Overview Table 80. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 82. Apogenix GmbH Recent Development Table 83. Alligator Bioscience AB Company Information Table 84. Alligator Bioscience AB Business Overview Table 85. Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 87. Alligator Bioscience AB Recent Development Table 88. Agenus Inc Company Information Table 89. Agenus Inc Business Overview Table 90. Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 92. Agenus Inc Recent Development Table 93. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US$ Million) Table 95. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2026) Table 96. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share Forecast by Country (2027-2032) Table 98. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US$ Million) Table 100. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2026) Table 101. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share Forecast by Country (2027-2032) Table 103. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US$ Million) Table 105. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2026) Table 106. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share Forecast by Country (2027-2032) Table 108. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US$ Million) Table 110. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2026) Table 111. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share Forecast by Country (2027-2032) Table 113. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US$ Million) Table 115. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2026) Table 116. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share Forecast by Country (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Tumor Necrosis Factor Receptor Superfamily Member 9 Product Image Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 5. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region: 2025 VS 2032 Figure 6. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2021-2032) Figure 7. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Ultra-41BBL Image Figure 13. Global Ultra-41BBL Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. PRS-342 Image Figure 15. Global PRS-342 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. ISAS-01 Image Figure 17. Global ISAS-01 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. EU-101 Image Figure 19. Global EU-101 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Others Image Figure 21. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type 2025 VS 2032 Figure 24. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Type (2021-2032) Figure 25. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Type (2021-2032) Figure 27. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Type (2021-2032) Figure 29. Gastric Cancer Image Figure 30. Global Gastric Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Lymphoma Image Figure 32. Global Lymphoma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Cervical Cancer Image Figure 34. Global Cervical Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Bladder Cancer Image Figure 36. Global Bladder Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Others Image Figure 38. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application 2025 VS 2032 Figure 41. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2021-2032) Figure 42. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2021-2032) Figure 43. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2021-2032) Figure 44. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2021-2032) Figure 45. Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2021-2032) Figure 46. Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Member 9 Players Market Share by Revenue in 2025 Figure 47. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 48. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 51. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 54. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 57. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 60. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country: 2021 VS 2025 VS 2032 Figure 62. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 63. Years Considered Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Ultra-41BBL
  • PRS-342
  • ISAS-01
  • EU-101
  • Others
Applications
  • Gastric Cancer
  • Lymphoma
  • Cervical Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Eli Lilly and Co
  • Pfizer Inc
  • Pieris Pharmaceuticals Inc
  • MacroGenics Inc
  • Juno Therapeutics Inc
  • BioInvent International AB
  • Apogenix GmbH
  • Alligator Bioscience AB
  • Agenus Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2021-2032)
  5. 1.4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2021-2026)
  6. 1.4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2027-2032)
  7. 1.5 Key Regions Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
  8. 1.5.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (2021-2032)
2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Ultra-41BBL
  3. 2.1.2 PRS-342
  4. 2.1.3 ISAS-01
  5. 2.1.4 EU-101
  6. 2.1.5 Others
  7. 2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
  8. 2.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Regions
  12. 2.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Type (2021-2026)
3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Gastric Cancer
  3. 3.1.2 Lymphoma
  4. 3.1.3 Cervical Cancer
  5. 3.1.4 Bladder Cancer
  6. 3.1.5 Others
  7. 3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
  8. 3.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Regions
  12. 3.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends
  2. 4.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Drivers
  3. 4.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Opportunities and Challenges
  4. 4.4 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (2021-2026)
  2. 5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Key Company Headquarters & Area Served
  4. 5.4 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company, Product Type & Application
  5. 5.5 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Member 9 Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Tumor Necrosis Factor Receptor Superfamily Member 9 Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Eli Lilly and Co
  2. 6.1.1 Eli Lilly and Co Company Information
  3. 6.1.2 Eli Lilly and Co Business Overview
  4. 6.1.3 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  6. 6.1.5 Eli Lilly and Co Recent Developments
  7. 6.2 Pfizer Inc
  8. 6.2.1 Pfizer Inc Company Information
  9. 6.2.2 Pfizer Inc Business Overview
  10. 6.2.3 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  12. 6.2.5 Pfizer Inc Recent Developments
  13. 6.3 Pieris Pharmaceuticals Inc
  14. 6.3.1 Pieris Pharmaceuticals Inc Company Information
  15. 6.3.2 Pieris Pharmaceuticals Inc Business Overview
  16. 6.3.3 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  18. 6.3.5 Pieris Pharmaceuticals Inc Recent Developments
  19. 6.4 MacroGenics Inc
  20. 6.4.1 MacroGenics Inc Company Information
  21. 6.4.2 MacroGenics Inc Business Overview
  22. 6.4.3 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  24. 6.4.5 MacroGenics Inc Recent Developments
  25. 6.5 Juno Therapeutics Inc
  26. 6.5.1 Juno Therapeutics Inc Company Information
  27. 6.5.2 Juno Therapeutics Inc Business Overview
  28. 6.5.3 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  30. 6.5.5 Juno Therapeutics Inc Recent Developments
  31. 6.6 BioInvent International AB
  32. 6.6.1 BioInvent International AB Company Information
  33. 6.6.2 BioInvent International AB Business Overview
  34. 6.6.3 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  36. 6.6.5 BioInvent International AB Recent Developments
  37. 6.7 Apogenix GmbH
  38. 6.7.1 Apogenix GmbH Company Information
  39. 6.7.2 Apogenix GmbH Business Overview
  40. 6.7.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  42. 6.7.5 Apogenix GmbH Recent Developments
  43. 6.8 Alligator Bioscience AB
  44. 6.8.1 Alligator Bioscience AB Company Information
  45. 6.8.2 Alligator Bioscience AB Business Overview
  46. 6.8.3 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  48. 6.8.5 Alligator Bioscience AB Recent Developments
  49. 6.9 Agenus Inc
  50. 6.9.1 Agenus Inc Company Information
  51. 6.9.2 Agenus Inc Business Overview
  52. 6.9.3 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  54. 6.9.5 Agenus Inc Recent Developments
7 North America
  1. 7.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  3. 7.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  3. 8.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  3. 10.3 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst